3//SEC Filing
OrbiMed Capital GP VII LLC 3
Accession 0001209191-18-061402
CIK 0001609727other
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 6:24 PM ET
Size
8.3 KB
Accession
0001209191-18-061402
Insider Transaction Report
Form 3
Synthorx, Inc.THOR
ORBIMED ADVISORS LLC
Director10% Owner
Holdings
- (indirect: See Footnote)
Series C Preferred Stock
→ Common Stock (3,952,719 underlying)
OrbiMed Capital GP VII LLC
10% Owner
Holdings
- (indirect: See Footnote)
Series C Preferred Stock
→ Common Stock (3,952,719 underlying)
Footnotes (4)
- [F1]The shares of Series C Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration. Each share of Series C Preferred Stock will automatically convert on a 1.60224-to-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]Share numbers give effect to the 1.60224-to-1 reverse stock split of the Issuer's Common Stock effected on November 26, 2018, which will be effective for the Preferred Stock upon its conversion to Common Stock upon the closing of the Issuer's initial public offering.
- [F3]These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the sole general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.
- [F4]This report on Form 3 is jointly filed by GP VII and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange At of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Peter A. Thompson ("Thompson"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Thompson is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Synthorx, Inc.
CIK 0001609727
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001760648
Filing Metadata
- Form type
- 3
- Filed
- Dec 5, 7:00 PM ET
- Accepted
- Dec 6, 6:24 PM ET
- Size
- 8.3 KB